NCT07599696 Speech Amplification Devices for Parkinson Disease: Talker- and Technology-Driven Enhancements
| NCT ID | NCT07599696 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Michigan State University |
| Condition | Parkinson Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2024-03-01 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2024-03-01 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The proposed research aims to investigate the use of speech amplification devices as a potential treatment option for people with Parkinson's disease and related disorders who exhibit hypophonia, a voice disorder that affects over half of those with Parkinson's disease. By characterizing the acoustic and perceptual effects of speech amplification and identifying ways to optimize outcomes through talker- and device-specific enhancements, this project seeks to develop personalized, evidence-based treatment options for hypophonia. The current proposal will move this effort forward by systematically eliciting and modifying speech amplification device output that leverage both behavioral and technological approaches.
Eligibility Criteria
Inclusion Criteria: * Dominant speakers of North American English * Have received a neurologist's diagnosis of Parkinson disease or parkinsonism (e.g., PSP/MSA/PSP) * Present with changes in their speech/voice Exclusion Criteria: * History of any other speech, language, or neurological concern other than Parkinson/parkinsonism. * Uncorrected hearing loss that exceeds a threshold of 40 dB HL in more than one ear (as per baseline screening audiometry) and/or use of a cochlear implant.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07599696 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, studying Parkinson Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07599696 currently recruiting?
Yes, NCT07599696 is actively recruiting participants. Contact the research team at thea@msu.edu for enrollment information.
Where is the NCT07599696 trial being conducted?
This trial is being conducted at East Lansing, United States.
Who is sponsoring the NCT07599696 clinical trial?
NCT07599696 is sponsored by Michigan State University. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.